Home › Urothelial (Transitional Cell) Carcinoma › Illinois › Chicago
Urothelial (Transitional Cell) Carcinoma clinical trials in Chicago, IL
14 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
RecruitingPhase 3
- University of Illinois, Chicago
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
- University of Illinois Cancer Center, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #26, Chicago
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
RecruitingObservational study
- Northwestern University, Chicago
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RecruitingPhase 2
- UChicago Medicine - River East, Chicago
- University of Chicago Medical Center, Chicago
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RecruitingPhase 1/2
- The University of Chicago Medical Center - Oncology, Chicago
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
RecruitingPhase 2
- Site 02-012 - University of Chicago, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Chicago
Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
RecruitingObservational study
- Jesse Brown Department Of Veterans Affairs Medical Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
RecruitingPhase 1
- University of Chicago, Chicago
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
RecruitingPhase 2
- Northwestern University, Chicago
Urothelial (Transitional Cell) Carcinoma trials in other cities
- Nashville, TN24 studies
- New York City, NY22 studies
- Houston, TX20 studies
- Edison, NJ18 studies
- Dallas, TX18 studies
- Los Angeles, CA17 studies
- Queens, NY16 studies
- Boston, MA13 studies
- Arlington, VA13 studies
- San Antonio, TX13 studies
- Austin, TX10 studies
- Orlando, FL10 studies
Other studies in Chicago
- Breast Cancer59 studies
- Non-Small Cell Lung Cancer59 studies
- Cancer (all types)51 studies
- Prostate Cancer45 studies
- Lung Cancer43 studies
- Metastatic Cancer42 studies
- Obesity40 studies
- Ovarian Cancer36 studies
- Colorectal Cancer32 studies
- Stroke31 studies
- Head and Neck Squamous Cell Carcinoma29 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.